Drug ID:Drug17
Drug Name:Fenofibrate
CID:3339
DrugBank ID:DB01039
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT05781698, , NCT05753267
Molecular Formula:C20H21ClO4
Molecular Weight:360.8 g/mol
Isomeric SMILES:CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
Synonyms:fenofibrate; 49562-28-9; Procetofen; Lipantil; Lipidil; Antara; Fenobrate; Triglide; Secalip; Fenoglide
Phase 0: 1
Phase 1: 20
Phase 2: 58
Phase 3: 58
Phase 4: 38
Description:An antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt149 3339 Fenofibrate 993 CDC25A Rattus norvegicus (Norway rat) 17264098 Fenofibrate results in increased expression of CDC25A mRNA
dt150 3339 Fenofibrate 23552 CDK20 Homo sapiens (human) 25572481 Fenofibrate results in increased expression of CDK20 mRNA
dt151 3339 Fenofibrate 1025 CDK9 Rattus norvegicus (Norway rat) 20828602 Fenofibrate affects the reaction [[streptozocin co-treated with dietary carbohydrates co-treated with dietary fats] affects the expression of CDK9 mrna]|fenofibrate affects the reaction [[streptozocin co-treated with dietary carbohydrates co-treated with
dt152 3339 Fenofibrate 1026 CDKN1A Rattus norvegicus (Norway rat) 18253720 [fenofibrate co-treated with diethylnitrosamine] results in decreased expression of CDKN1A mRNA
dt153 3339 Fenofibrate 1026 CDKN1A Rattus norvegicus (Norway rat) 25596134 Fenofibrate results in decreased expression of CDKN1A mRNA
dt154 3339 Fenofibrate 1027 CDKN1B Homo sapiens (human) 29134746 Estradiol inhibits the reaction [fenofibrate results in decreased expression of CDKN1B protein]|fenofibrate results in decreased expression of CDKN1B protein|esr1 protein inhibits the reaction [fenofibrate results in decreased expression of CDKN1B protein
dt155 3339 Fenofibrate 1027 CDKN1B Rattus norvegicus (Norway rat) 18253720 [fenofibrate co-treated with diethylnitrosamine] results in decreased expression of CDKN1B mRNA
dt156 3339 Fenofibrate 145508 CEP128 Rattus norvegicus (Norway rat) 32741897 Fenofibrate results in increased expression of CEP128 mRNA
dt157 3339 Fenofibrate 91012 CERS5 Rattus norvegicus (Norway rat) 25596134 Fenofibrate results in decreased expression of CERS5 mRNA
dt158 3339 Fenofibrate 1066 CES1 Rattus norvegicus (Norway rat) 18253720 [fenofibrate co-treated with diethylnitrosamine] results in decreased expression of CES1 mRNA

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05781698 Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis PHASE2 COMPLETED Tanta University Inflammatory Bowel Diseases DRUG: Mesalamine|DRUG: Fenofibrate Details
NCT05753267 Fenofibrate in Ulcerative Colitis PHASE2|PHASE3 RECRUITING Tanta University Inflammatory Bowel Diseases DRUG: Mesalamine|DRUG: Fenofibrate 160mg Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Fenofibrate inhibited the differentiation of T helper 17 cells in vitro

PMID: 22792085
Year: 2012
Relationship Type: Association Score: 6.1

Uncontrolled activity of T cells mediates autoimmune and inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, rheumatoid ar…

View Details